Clínica Mayo de UMCB SRL - Tucumán
Clínica Mayo de UMCB SRL cuenta con acreditación ITAES en la ciudad de San Miguel de Tucumán cuenta con el Centro de Investigación a cargo del Director del Dpto de Investigación Clínica: Dr Conrado Llapur, 3 Coordinadoras, más de 10 investigadores clínicos con experiencia en diferentes especialidades (Cardiología, Endocrinología, Neumonología, Infectología, Reumatología, Pediatría, Ginecología y Obstetricía, Psiquiatría) 1 bioquímico9 de Julio 259, San Miguel de Tucumán
Select an option
I am a doctor
I am a sponsor
Specializations
Cardiología
Endocrinología
Neumología
Infectología
Reumatología
Pedriatría
Ginecología
Our team
Medical staff
Priscila Maria Marcaida
Yessika Soria
Maria De la Rosa
Natalia Elizabeth Vega
Francisco Colombres
Maria Virginia Mansilla
Conrado Juan Llapur
Maria Eugenia Valdez
Florencia Caffarena
Open studies
Lupus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus - AMETHYST - BiogenSee more
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) - Immunovant Sciences GmbHSee more
Chronic obstructive pulmonary disease
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease - PRESTO - AstraZenecaSee more
Heart failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure - EASi-HF - Boehringer IngelheimSee more
Lung cancer
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
Rare diseases
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State - HZNP-DAZ-303 - AmgenSee more
Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria - EMBARQ-CSU1 - Celldex TherapeuticsSee more
